Antibiotic Categorization into Therapeutic Classes
Antibiotics are categorized into three primary groups using the WHO AWaRe framework: Access, Watch, and Reserve antibiotics, which stratifies agents based on resistance potential, stewardship priorities, and appropriate clinical use rather than traditional mechanism-based classifications. 1
The AWaRe Classification System
The WHO Expert Committee established this framework to guide antibiotic selection and stewardship globally:
Access Group
- Definition: First- or second-choice empiric treatment options for common clinical infections
- Characteristics:
- Good clinical activity against commonly susceptible bacteria
- Lower resistance potential compared to other groups
- Should be widely available, affordable, and of assured quality
- Narrow-spectrum agents with favorable risk-benefit ratios
- Clinical application: These should be accessible in all healthcare facilities as frontline options 1
Watch Group
- Definition: Antibiotics with greater concerns about toxicity or resistance development potential
- Characteristics:
- Still recommended as first- or second-choice for specific indications
- Includes highest priority critically important antimicrobials (fluoroquinolones, carbapenems)
- Broader-spectrum agents with higher reported resistance rates
- Key targets for antibiotic stewardship and monitoring programs
- Critical caveat: Access and Watch groups are not mutually exclusive—both require availability, but Watch antibiotics demand restricted, indication-specific use 1
Reserve Group
- Definition: Last-resort options for multidrug-resistant organisms
- Characteristics:
- Used only when other alternatives are inadequate or have failed
- Show consistent activity against organisms resistant to first- and second-choice options
- Reserved for severe/life-threatening infections from multidrug-resistant bacteria
- Major targets for intensive stewardship programs
- Only eight antibiotics currently designated in this category
- Stewardship priority: These require the highest level of monitoring and reporting 1
Alternative Classification Systems
While AWaRe is the guideline-endorsed framework, antibiotics can also be categorized by:
Mechanism of Action (Traditional approach)
- Cell wall synthesis inhibitors: β-lactams, fosfomycin, vancomycin 2, 3, 4
- Protein synthesis inhibitors: Tetracyclines, macrolides, aminoglycosides, oxazolidinones 2, 3, 4
- Nucleic acid synthesis inhibitors: Fluoroquinolones (DNA), rifampicin (RNA) 2, 3, 4
- Membrane-active agents: Polymyxins, lipopeptides 4, 5
Structural Class (Medicinal chemistry approach)
Major classes include β-lactams, glycopeptides, tetracyclines, fluoroquinolones, macrolides, aminoglycosides, oxazolidinones, polymyxins, and lipopeptides, with further subdivision by generation within each class 2, 5
Clinical Implementation
The AWaRe framework supersedes mechanism-based classification for clinical decision-making because it directly addresses antimicrobial resistance and stewardship priorities. The traditional mechanism-based categorization remains useful for understanding drug interactions and resistance mechanisms, but should not drive empiric prescribing decisions 1.
Key Stewardship Principle
The goal is achieving ≥60% of antibiotic consumption from the Access group nationally, with Watch antibiotics reserved for specific indications where Access options are inadequate, and Reserve antibiotics protected through intensive monitoring 1.
Common Pitfall
Clinicians often default to broader-spectrum Watch antibiotics when narrower Access agents would suffice. Always start with Access antibiotics unless specific resistance patterns, severity, or pathogen characteristics mandate escalation to Watch or Reserve categories 1.